Rhythm Pharmaceuticals (RYTM) Change in Receivables (2022 - 2026)

Rhythm Pharmaceuticals (RYTM) has 5 years of Change in Receivables data on file, last reported at $8.1 million in Q1 2026.

• On a quarterly basis, Change in Receivables rose 1280.49% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $16.4 million, a 422.91% increase from a year earlier, with the FY2025 full-year figure at $7.6 million, up 107.68% from the prior year.
• Change in Receivables for Q1 2026 stood at $8.1 million, up from -$6.2 million in the prior quarter.
• Over the last five years, Change in Receivables for RYTM reached as high as $8.1 million in Q1 2026 and fell as low as -$6.2 million in Q4 2025.
• Historically, Change in Receivables has averaged $2.1 million across 5 years, with a median of $1.7 million in 2024.
• Across the five-year window, Change in Receivables plunged 677.71% in 2025 and soared 1280.49% in 2026, its largest moves.
• Year by year, Change in Receivables stood at $2.9 million in 2022, then sank by 88.74% to $326000.0 in 2023, then plunged by 343.56% to -$794000.0 in 2024, then plunged by 677.71% to -$6.2 million in 2025, then jumped by 231.34% to $8.1 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $8.1 million in Q1 2026, -$6.2 million in Q4 2025, and $6.6 million in Q3 2025.